Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of diabetic nephropathy by treating hyperfiltration in subclinical diabetic nephropathy
ChiCTR1800014345Phase 3Recruiting
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dapagliflozin, losartan and empagliflozin in diabetic glomerulosclerosis, sponsored by Zhu Xianyi Memorial Hospital. Started Feb 2018; status: recruiting.
02
Drugs
dapagliflozinlosartanempagliflozin
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR1800014345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014345.